<DOC>
	<DOCNO>NCT00675870</DOCNO>
	<brief_summary>The purpose study determine whether NRX 195183 effective treatment relapse refractory Acute Promyelocytic Leukemia</brief_summary>
	<brief_title>Study NRX 195183 Therapy Patients With Relapsed Refractory Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>A common current therapeutic approach APL use oral ATRA chemotherapy induction consolidation . This approach significantly improve survival newly diagnose APL patient . However , approximately 30 % patient relapse . Recently , approach involve combination oral ATRA arsenic trioxide test . The prognosis relapse patient poor . This study seek investigate NRX 195183 monotherapy patient fail resistant intolerant prior therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>Clinical diagnosis APL morphology FAB M3 variant confirm RTPCR assay chromosome analysis/FISH showing ( 15:17 ) translocation . Patients must also relapse , resistance intolerance one follow therapy : ATRA Cytotoxic chemotherapy Arsenic trioxide Patients must 18 old . Bilirubin equal le 1.5 time upper limit normal . Creatinine equal le 1.5 time upper limit normal . Patients enter study nonpregnant nonnursing plan become pregnant treatment . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control . There extremely high risk severely deform infant result NRX 195183 administer pregnancy . NonAPL , AML patient exclude study . Other serious illness would limit survival 6 month . Psychiatric condition would prevent compliance treatment informed consent . Uncontrolled severe cardiovascular disease . This would include history recent acute myocardial infarction , uncontrolled congestive heart failure , active angina . AIDS HIV positive patient , although HIV test require accrual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Acute Promyelocytic Leukemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>APL</keyword>
	<keyword>ATRA</keyword>
	<keyword>Tretinoid</keyword>
	<keyword>Vesanoid</keyword>
	<keyword>Retinoic Acid Receptor Alpha</keyword>
	<keyword>All Trans Retinoic Acid</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>Trisenox</keyword>
	<keyword>Retinoid</keyword>
	<keyword>Relapsed Refractory Acute Promyelocytic Leukemia</keyword>
</DOC>